2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
4
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Rheumatoid Arthritis, Systemic Juvenile
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Periodic Fevers Syndrome
1
Pancreatic Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mevalonate Kinase Deficiency
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma
1
Leukemia, Myelomonocytic, Chronic
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Clonal Cytopenia of Undetermined Significance
1
Carcinoma, Renal Cell
1
Carcinoma, Ductal
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Arthritis, Juvenile
1
Arthralgia
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
canakinumab
×
Clear all
NCT03484923
2024-06-18
PLATforM
Novartis
Phase 2
Completed
196 enrolled
22 charts